Anthracycline Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antibody discovery market size has grown rapidly in recent years. It will grow from $8.96 billion in 2024 to $9.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to surge in investment for drug discovery, growing investment in research and development activities, and presence of various healthcare research centers and academic institutions.

The antibody discovery market size is expected to see rapid growth in the next few years. It will grow to $14.6 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for antibody drug discovery services and platforms, surge in funding for the development of novel technologies, growing demand for precision therapeutics, and broadening the utilization of antibodies beyond their conventional therapeutic roles. Major trends in the forecast period include increased research and development activities, growing demand for monoclonal antibodies, increased adoption of advanced technologies, growing demand for targeted therapeutics, and development of novel antibody formats.

The antibody discovery market is poised for significant growth due to the increasing demand for precision therapeutics, also known as personalized therapeutics. This approach tailors medical treatments to individual patient characteristics, enhancing effectiveness. Antibody discovery plays a pivotal role in precision therapeutics by facilitating the development of targeted therapies such as monoclonal antibodies, which interact precisely with disease-related molecules or cells. Notably, in January 2023, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% of therapeutic NMEs classified as personalized medicines. This underscores the pivotal role of precision therapeutics in driving the antibody discovery market's growth.

Leading players in the antibody discovery market are investing in cutting-edge technologies to streamline and enhance antibody development processes. One notable innovation is the emergence of AI-based computational antibody drug discovery platforms, which leverage artificial intelligence and computational techniques to expedite antibody identification and optimization. For example, in October 2023, SwiftPharma BV introduced an AI-driven antibody discovery platform. This platform integrates artificial intelligence, big data, machine learning, and phage display techniques to swiftly predict high-specificity and high-affinity antibody-antigen binding. By mimicking natural language processing, this approach generates diverse antibody variations, enabling comprehensive antibody library creation with unprecedented efficiency. This advanced system significantly accelerates the discovery of potential antibody drugs.

In July 2024, Pentixapharm, a Germany-based biotech company specializing in radiopharmaceuticals, acquired Glycotope's target discovery unit for an undisclosed sum. This acquisition supports Pentixapharm’s strategy to enhance its oncology pipeline by converting preclinical antibodies targeting various cancer indications into radiopharmaceuticals. In addition to the preclinical assets, Pentixapharm acquired Glycotope’s laboratories, cell banks, tumor target database, and equipment, thereby further enriching its Intellectual Property portfolio beyond the CXCR4 receptor. Glycotope, also based in Germany, is a biotechnology firm focused on developing glyco-optimized antibodies for cancer immunotherapies.

Major companies operating in the antibody discovery market report are Danaher Corporation, Eurofins Scientific, Sartorius AG, Charles River Laboratories, Bruker Corporation, WuXi Biologics, Genmab A/S, Evotec, Cambrex corporation, ChemPartner, Aragen life science Pvt ltd, Genscript Technology Corporation, Biocytogen, Alcami Corporation Inc, Twist Bioscience, BioDuro-Sundia, Fairjourney Biologics S.A, Harbour BioMed, Rockland Immunochemicals, Creative Biolabs, Synbio technologies, ImmunoPrecise, Ablexis, Myrio Therapeutics, Antibody Solutions, MabSilico.

North America was the largest region in the antibody discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody discovery market includes revenues earned by entities by providing services such as antigen identification, immunization, antibody generation, screening, and characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody discovery market also includes sales of antibody libraries, phage display kits, antigen proteins, and antibody screening platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Antibody discovery is the process of identifying and developing antibodies, which are proteins generated by the immune system to defend the body against harmful substances such as bacteria and viruses. Antibodies, also known as immunoglobulins, play a vital role in the immune response by recognizing and binding to specific molecules known as antigens.

The primary methods employed in antibody discovery include phage display, hybridoma, and others. Phage display is a molecular biology technique utilized for the study and selection of peptides or proteins, typically antibodies, that exhibit high affinity to a target of interest. This method is widely applied in antibody discovery to generate and select antibodies with specific binding properties. Various types of antibodies, including humanized antibodies, human antibodies, chimeric antibodies, and murine antibodies, find application among end users in the pharmaceutical and biotechnology industries, research laboratories, and academic institutions.

The antibody discovery research report is one of a series of new reports that provides antibody discovery market statistics, including the antibody discovery industry's global market size, regional shares, competitors with an Antibody discovery market share, detailed antibody discovery market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery industry. This antibody discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.